Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-associated mortality with continued poor outcome and a short-lived treatment response to conventional therapy. However, with the rapidly evolving field of precision oncology, new and novel genomic information is emerging, identifying tumor subtypes by revealing somatic and germline mutations. There is growing interest in determining the tumor BRCA status to guide potential PARP inhibitor targeted therapy and for evaluating tumor microsatellite instability status for immune checkpoint inhibitor therapy which has been reported in up to 3% of PDAC patients. Precision immuno-oncology and therapies targeting the stroma are a developing oncologic field but to date the impact upon patients with PDAC has not been established. The ability to complete tumor genotyping and gene expression assessments and to determine immunotherapy eligibility have renewed optimism that patients with PDAC may soon have access to effective treatment strategies.